Anti-estrogens and other agents used in ER+ breast cancer treatment such as PI3K/mTOR inhibitors and chemotherapeutics have been reported to upregulate Bcl-2 proteins, priming the cell for BH3 mimetic activity [114,130,144]. Here, MTOR is linked to breast cancer.